振东制药 reported revenue of ¥1.10B for the period ended 2026-06-30, -24.7% year on year. Net income was ¥-0.10B, a -8.7% net margin on a 53.1% gross margin. The largest revenue line is 中药 at 58% of the total. Free cash flow for the period was ¥-0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.10B | -24.7% |
| Gross profit | ¥0.58B | — |
| Operating income | ¥-0.09B | — |
| Net income | ¥-0.10B | -1565.4% |
| Gross margin | 53.1% | Net margin -8.7% |
| Revenue Q/Q | -31.1% | — |
| Segment | Revenue | Share |
|---|---|---|
| 中药 | ¥0.64B | 58.1% |
| 化药 | ¥0.41B | 37.2% |
| 非药品收入 | ¥0.05B | 4.2% |
| 其他(补充) | ¥0.01B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.51B | 46.9% |
| R&D | ¥0.09B | 8.2% |
| SG&A | ¥0.55B | 50.5% |
| Tax & other | ¥0.00B | 0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥4.27B |
| Total liabilities | ¥1.06B |
| Shareholders' equity | ¥3.22B |
| Equity / assets | 75.3% |
| Operating cash flow | ¥-0.04B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.06B |
| Cash conversion (OCF / net income) | 365% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新研股份 ・ 秀强股份 ・ 华中数控 ・ 雷曼光电 ・ 先锋新材 ・ 通源石油 ・ 天瑞仪器 ・ 东方国信 ・ ST迪威迅 ・ 万达信息 ・ 天晟新材 ・ 汉得信息
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies